AURA - CIK 0001501796
The table below shows Aura Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.79M | $47.55M | $107.37M | $38.23M | $25.41M | $30.07M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $118.50M |
| $170.12M |
| $183.96M |
| $134.52M |
| $183.48M |
| $195.60M |
| Property, plant & equipment | $2.47M | $2.63M | $2.86M | $3.11M | $3.33M | $3.33M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $137.68M | $190.02M | $204.40M | $155.40M | $205.34M | $218.28M |
| Accounts payable | $2.57M | $1.89M | $1.29M | $2.01M | $1.99M | $1.46M |
| Total current liabilities | $16.71M | $18.82M | $14.85M | $12.16M | $14.71M | $10.55M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $30.43M | $33.36M | $29.77M | $27.43M | $30.67M | $26.83M |
| Retained earnings | -$514.10M | -$454.86M | -$428.73M | -$401.71M | -$348.39M | -$327.35M |
| Total equity | $107.25M | $156.67M | $174.63M | $127.97M | $174.67M | $191.45M |